---
title: "Immuneering To Present New Phase 2a Data For Atebimetinib In Treating Pancreatic Cancer On June 1"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283630575.md"
description: "Immuneering Corporation (IMRX) will present updated Phase 2a trial data for Atebimetinib in treating pancreatic cancer at the ASCO meeting on June 1, 2026. The trial evaluates Atebimetinib with modified gemcitabine/nab-paclitaxel for advanced pancreatic cancer. The presentation will include survival data from 55 patients. The company plans to initiate a Phase 3 trial, named MAPKeeper, by mid-2026. IMRX shares closed at $5.55, up 0.36%."
datetime: "2026-04-22T09:10:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283630575.md)
  - [en](https://longbridge.com/en/news/283630575.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283630575.md)
---

# Immuneering To Present New Phase 2a Data For Atebimetinib In Treating Pancreatic Cancer On June 1

(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, is expected to present updated data from its Phase 2a trial of Atebimetinib in combination with modified gemcitabine/nab-paclitaxel in treating pancreatic cancer at the annual meeting of the American Society of Clinical Oncology (ASCO) on June 1, 2026.

Atebimetinib (IMM-I-104) is a once-daily, oral, investigational Deep Cyclic inhibitor of MEK that provides more durable anti-tumor activity to improve survival across different indications, including pancreatic cancer.

The Phase 2a trial evaluates atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) to treat patients with advanced or metastatic pancreatic cancer as a first-line treatment. The presentation will include survival data across 55 first-line patients, comprising the initial cohort of 34 patients and an additional 21 patients.

The company is advancing atebimetinib, and expects to initiate a Phase 3 trial in combination with chemotherapy for treating pancreatic cancer, dubbed MAPKeeper trial by mid-2026.

IMRX closed Tuesday at $5.55, up 0.36%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [IMRX.US](https://longbridge.com/en/quote/IMRX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)